<DOC>
	<DOCNO>NCT02834806</DOCNO>
	<brief_summary>This study aim assess device success safety Medinol 's Drug Eluting Stent - BioNIR - modify delivery system . The BioNIR Ridaforolimus Eluting Coronary Stent System single use device/drug combination product comprising : - A mounted Cobalt Chromium ( CoCr ) alloy base stent - A Rapid Exchange ( RX ) delivery system - A polymer matrix coat - Poly n-butyl methacrylate ( PBMA ) CarboSil® - Ridaforolimus drug - CAS Registry Number : 572924-54-0 It indicate improve coronary luminal diameter patient symptomatic heart disease due lesion vessel reference diameter 2.5 mm 4.25 mm , include complex lesion .</brief_summary>
	<brief_title>BIONICS Israel Trial</brief_title>
	<detailed_description>This prospective , multi-center , single arm , open label , clinical trial . Lesions plan treat must declare recorded time enrollment . Planned stag procedure , necessary , must declare immediately post procedure . Clinical follow-up perform 30 day . Telephone follow-ups perform 6 month 1 year post procedure .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patient indication PCI include angina ( stable unstable ) , silent ischemia ( absence symptom visually estimate target lesion diameter stenosis ≥70 % , positive noninvasive stress test , FFR ≤0.80 must present ) , NSTEMI , recent STEMI . For STEMI time presentation first treat hospital , whether transfer facility study hospital , must &gt; 24 hour prior enrollment enzyme level ( CKMB Troponin ) demonstrate either enzyme level peak . 2 . Nontarget vessel PCI allow prior enrollment depend time interval condition follow : During Baseline Procedure : PCI nontarget vessel perform baseline procedure immediately prior enrollment successful uncomplicated define : &lt; 50 % visually estimate residual diameter stenosis , TIMI Grade 3 flow , dissection ≥ NHLBI type C , perforation , persistent ST segment change , prolong chest pain , TIMI major BARC type 3 bleeding . Less 24 hour prior Baseline Procedure : Not allow ( see exclusion criterion # 2 ) . 24 hours30 day prior Baseline Procedure : PCI nontarget vessel 24 hour 30 day prior enrollment successful uncomplicated define . In addition , case nontarget lesion PCI occur 2472 hour prior baseline procedure , least 2 set cardiac biomarkers must draw least 6 12 hour nontarget vessel PCI . If cardiac biomarkers initially elevate local laboratory upper limit normal , serial measurement must demonstrate biomarkers fall . Over 30 day prior Baseline Procedure : a. PCI nontarget vessel perform great 30 day prior procedure whether successful uncomplicated . 3 . Patient legal guardian willing able provide inform write consent comply followup visit test schedule . Angiographic inclusion criterion ( visual estimate ) : 4 . Target lesion ( ) must locate native coronary artery bypass graft conduit visually estimate diameter ≥2.5 mm ≤4.25 mm . 5 . Complex lesion allow include calcified lesion ( lesion preparation scoring/cutting rotational atherectomy allow ) , presence thrombus , CTO , bifurcation lesion ( except note exclusion criterion # 30 ) , ostial RCA lesion , tortuous lesion , bare metal stent restenotic lesion , protect leave main lesion , saphenous vein graft lesion . 6 . Overlapping stent allow . General 1 . STEMI within 24 hour initial time presentation first treat hospital , whether transfer facility study hospital enzyme level ( either CKMB Troponin ) peak . 2 . PCI within 24 hour precede baseline procedure . 3 . Nontarget lesion PCI target vessel within 12 month baseline procedure . 4 . History stent thrombosis . 5 . Cardiogenic shock ( defined persistent hypotension ( systolic blood pressure &lt; 90 mm/Hg 30 minute ) require pressor hemodynamic support , include IABP . 6 . Subject intubate . 7 . Known LVEF &lt; 30 % . 8 . Relative absolute contraindication DAPT 6 month nonACS patient 12 month ACS patient ( include plan surgery delay , subject indicate chronic oral anticoagulant treatment ) . 9 . Calculated creatinine clearance &lt; 30 mL/min use CockcroftGault equation ( &lt; 40 mL/min subject participate angiographic followup substudy ) . 10 . Hemoglobin &lt; 10 g/dL . 11 . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 . 12 . White blood cell ( WBC ) count &lt; 3,000 cells/mm3 . 13 . Clinically significant liver disease . 14 . Active peptic ulcer active bleeding site . 15 . Bleeding site within prior 8 week require active medical surgical attention . 16 . If femoral access plan , significant peripheral arterial disease precludes safe insertion 6F sheath . 17 . History bleed diathesis coagulopathy refuse blood transfusion . 18 . Cerebrovascular accident transient ischemic attack within past 6 month , permanent neurologic defect attribute CVA . 19 . Known allergy study stent component , cobalt , nickel , chromium , molybdenum , Carbosil® , PBMA , polymer , limus drug ( ridaforolimus , zotarolimus , tacrolimus , sirolimus , everolimus , similar drug analogue derivative similar compound ) . 20 . Known allergy protocolrequired concomitant medication aspirin , DAPT ( clopidogrel , prasugrel , ticagrelor ) , heparin bivalirudin , iodinate contrast adequately premedicated . 21 . Any comorbid condition may cause noncompliance protocol ( e.g . dementia , substance abuse , etc . ) reduce life expectancy &lt; 24 month ( e.g . cancer , severe heart failure , severe lung disease ) . 22 . Patient participate plan participate investigational drug device clinical trial reach primary endpoint . 23 . Women pregnant breastfeeding ( woman childbearing potential must negative pregnancy test within one week treatment ) . 24 . Women intend become pregnant within 12 month baseline procedure ( woman childbearing potential sexually active must agree use reliable method contraception time screen 12 month baseline procedure ) . 25 . Patient receive organ transplant wait list organ transplant . 26 . Patient receive schedule receive chemotherapy within 30 day time baseline procedure . 27 . Patient receive oral intravenous immunosuppressive therapy know lifelimiting immunosuppressive autoimmune disease ( e.g. , HIV ) . Corticosteroids allow . Angiographic Exclusion Criteria ( visual estimate ) : 28 . More 100 mm length plan stenting entire coronary tree . 29 . Unprotected leave main lesion ≥30 % , plan leave main intervention . 30 . Ostial LAD LCX lesion ( stenting diseased segment within 5 mm unprotected leave main coronary artery ) . 31 . Bifurcation lesion plan dual stent implantation . 32 . Stenting lesion due DES restenosis . 33 . Another lesion target nontarget vessel ( include side branch ) present require high probability require PCI within 12 month baseline procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>